Clonal haematopoiesis of indeterminate potential and epigenetic age acceleration: Systematic review and meta-analysis.

Ageing Res RevJul 16, 2026 (epub)
Clinical ResearchHematology

Matthew W Simonson, Sayan Mitra, Jian Hua Tay et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the relationship between clonal haematopoiesis of indeterminate potential (CHIP) and epigenetic age acceleration (EAA) in a population of 7483 individuals aged 55-79. The analysis revealed that individuals with CHIP had significantly higher EAA compared to those without CHIP, with a mean difference of 2.84 years for Horvath1Age IEAA.

Key findings

  • CHIP individuals had higher EAA than no-CHIP individuals, with a mean difference of 2.84 years for Horvath1Age IEAA.
  • Larger clones were associated with higher EAA.
  • TET2-mutated CHIP showed larger effect sizes and more consistent associations with EAA than DNMT3A-mutated CHIP.
  • Higher EAA may modify morbidity and mortality risks in individuals with CHIP.

Why it matters

Understanding the association between CHIP and EAA could provide insights into the biological mechanisms of aging and potential prognostic indicators for morbidity and mortality in older adults.

Source

PubMed · PMID 42463064

Published in Ageing Res Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.